Akèy › Timè nan sèvo › Utah
Etid klinik pou Timè nan sèvo nan Utah
8 etid pou Timè nan sèvo ap chèche patisipan nan sit nan Utah.
Vil nan Utah
Tèks ofisyèl etid la (Anglè)
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
- Huntsman Cancer Institute, University of Utah, Salt Lake City
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07326566A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
- Huntsman Cancer Institute/University of Utah, Salt Lake City
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT04511013Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma
- Primary Children's Hospital, Salt Lake City
Ap rekriteFaz 2
59 Months · Tout sèks · Mizajou Sep 15, 2026 · NCT05535166A Phase 1/1b Study of IAM1363 in HER2 Cancers
- START Mountain Region, West Valley City
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT06253871Stereotactic Radiosurgery Dose Escalation for Brain Metastases
- Huntsman Cancer Institute, Salt Lake City
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 2, 2026 · NCT02390518Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
- University of Utah, Huntsman Cancer Institute, Salt Lake City
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Apr 13, 2026 · NCT06810544Guided Meditation During Radiation Therapy for Brain Tumors
- Huntsman Cancer Institute, Salt Lake City
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Mar 20, 2026 · NCT06165653Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma
- Huntsman Cancer Institute, Salt Lake City
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Dec 3, 2025 · NCT06194929Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.